Cardiology

ELIXA trial shows CV safety of Lixisenatide

In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the ...

Diabetes

Antibiotic use linked to type 2 diabetes diagnosis

People who developed Type 2 diabetes tended to take more antibiotics in the years leading up to the diagnosis than people who did not have the condition, according to a new study published in the Endocrine Society's Journal ...

Diabetes

Long-acting analog insulin doesn't up AMI risk in T2DM

(HealthDay)—For patients with type 2 diabetes, the risk of acute myocardial infarction (AMI) is not significantly different for long-acting insulin analogs versus other basal insulin therapies, according to a study published ...

page 2 from 100